

ASX RELEASE**Resignation of Chief Financial Officer**

25 March 2026 - Global analytical science and device company Trajan Group Holdings Limited (ASX: TRJ) (Trajan or the Company) has today announced the resignation of Chief Financial Officer and Joint Company Secretary, Mr Alister Hodges.

Mr Hodges joined Trajan upon the acquisition of SGE Analytical Science in May 2013. Alister has supported the growth of Trajan over that time and managed the finance and IT teams. He has also been joint Company Secretary since IPO in June 2021.

Mr Hodges will cease his employment with Trajan on 11 November 2026. The Board will now commence a formal executive search to appoint a successor; interim arrangements are in place to ensure business continuity.

Stephen Tomisich, CEO and Managing Director of Trajan said "I'd like to thank Alister for his commitment to the business for more than 15 years, supporting our growth, smooth post-acquisition integrations and a successful IPO process. On behalf of the Board and the entire team at Trajan we wish him every success in his future endeavors."

Authorised for ASX release by the Board of Directors of Trajan Group Holdings Limited

END

Contact:**Investors**

investorrelations@trajanscimed.com

Media

media@trajanscimed.com

About Trajan

Trajan is a global developer and manufacturer of analytical and life sciences products and devices founded to enable science that benefits people by enriching personal health through scientific tools and solutions. These products and solutions are used in the analysis of biological, food, and environmental samples. Trajan has a portfolio and pipeline of new technologies which support the move towards decentralised, personalised data-based healthcare.

Trajan is a global organisation of more than 600 people, with seven manufacturing sites across the US, Australia, Europe and Malaysia, and operations in Australia, the US, Asia, and Europe.